-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
China News Service, Taiyuan, October 18 (Wu Qiong) The reporter learned from the Shanxi Provincial Medical Insurance Bureau on the 18th that from October 20th, all public medical institutions in Shanxi Province will fully implement the national fifth batch of 61 drugs and the "eight provinces and two The result of the selection of 10 kinds of medicines in the district alliance allows patients to enjoy the effect of price reduction of medicines purchased in quantity
.
It is understood that the country’s fifth batch of centralized drug procurement has a total of 61 drugs and 251 products selected, with an average price reduction of 56%
.
This collection of products covers common diseases such as hypertension, coronary heart disease, diabetes, anti-allergic, anti-infection, gastrointestinal diseases, and chronic disease drugs, as well as drugs for major diseases such as lung cancer, breast cancer, and colorectal cancer.
The treatment costs for related patients will be significant.
Lower
.
Among them, esomeprazole for injection, which is commonly used in clinical treatment of digestive ulcers, decreased by 96.
2%, fasudil hydrochloride injection, which improves brain tissue microcirculation, decreased by 95.
9%, and gemcitabine hydrochloride for injection, an antitumor drug, decreased by 92.
0%.
%, the anticoagulant rivaroxaban tablets dropped by 98.
3%
.
Shanxi participated in Heilongjiang and other "eight provinces and two regions" inter-provincial alliance drug centralized procurement, a total of 10 drugs and 12 product regulations were selected, with an average decrease of 66.
7%
.
Among them, the price of sodium hyaluronate injection for bone diseases decreased from 123.
4 yuan to 44.
5 yuan, a decrease of 63.
9%; the price of antibiotic drug Biapenem fell from 113 yuan to 30 yuan, a decrease of 73.
5%
.
While fully implementing the results of price reductions for 71 selected drugs across the province, Shanxi will implement prepayment of medical insurance funds, coordination of medical insurance payment standards and purchase prices, strengthen management of clinical rational use of drugs, incentive assessment of medical insurance fund balance retention, and strengthen quality supervision of selected drugs And other measures to promote hospitals to give priority to the use of selected drugs with reliable quality and reasonable prices
.
After the implementation of these two batches of drugs, the number of national and provincial centralized procurement drugs implemented in Shanxi will reach 277, with an average drop of more than 50%. .
The Shanxi Provincial Medical Insurance Bureau stated that in the next step, Shanxi will continue to play an important role in enhancing people’s well-being, promoting the joint reform of the three medicines, and promoting the healthy development of the pharmaceutical industry.
It will take centralized and quantitative procurement of medicines as a coordinated promotion of medical services.
An important measure for supply-side reforms, to promote the normalization and institutionalization of centralized drug procurement, reduce the burden on people's use of drugs, and better ensure that people have medical treatment
.
(over)